AR094960A1 - Anticuerpos de quimiocina pan-elr⁺ cxc - Google Patents
Anticuerpos de quimiocina pan-elr⁺ cxcInfo
- Publication number
- AR094960A1 AR094960A1 ARP140100675A ARP140100675A AR094960A1 AR 094960 A1 AR094960 A1 AR 094960A1 AR P140100675 A ARP140100675 A AR P140100675A AR P140100675 A ARP140100675 A AR P140100675A AR 094960 A1 AR094960 A1 AR 094960A1
- Authority
- AR
- Argentina
- Prior art keywords
- gro
- seq
- antibodies
- antibody
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Se proveen anticuerpos que específicamente unen siete quimiocinas ELR⁺ CXC humanas. Los anticuerpos son útiles para el tratamiento de diversas enfermedades inflamatorias/autoinmunes, tal como enfermedad inflamatoria intestinal (IBD), psoriasis en placas, pustulosis palmoplantar; y cáncer, tal como el cáncer renal o cáncer de ovario. Reivindicación 1: Un anticuerpo que neutraliza Gro-a, Gro-b, Gro-g, ENA-78, GCP-2, NAP-2, e IL-8 humana. Reivindicación 7: Un anticuerpo que une Gro-a, Gro-b, Gro-g, ENA-78, GCP-2, NAP-2, e IL-8 humana, el anticuerpo que comprende una cadena ligera y una cadena pesada, en donde la cadena ligera comprende una región variable de cadena ligera (LCVR) y la cadena pesada comprende una región variable de cadena pesada (HCVR), en donde la LCVR comprende LCDR1, LCDR2, LCDR3 y la HCVR comprende HCDR1, HCDR2, HCDR3, en donde LCDR1 es RASQSISNNLH (SEQ ID Nº 7), LCDR2 es YTSRSVS (SEQ ID Nº 8), LCDR3 es GQNNEWPEV (SEQ ID Nº 9), HCDR1 es GYEFTSYWIH (SEQ ID Nº 10), HCDR2 es NISPNSGSANYNEKFKS (SEQ ID Nº 11), y HCDR3 es EGPYSYYPSRXᵃᵃYYGSDL (SEQ ID Nº 20) en donde Xᵃᵃ es E o Q.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792800P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094960A1 true AR094960A1 (es) | 2015-09-09 |
Family
ID=50343858
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100675A AR094960A1 (es) | 2013-03-15 | 2014-02-28 | Anticuerpos de quimiocina pan-elr⁺ cxc |
| ARP220101240A AR125831A2 (es) | 2013-03-15 | 2022-05-10 | Anticuerpos de quimiocina pan-elr⁺ cxc |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101240A AR125831A2 (es) | 2013-03-15 | 2022-05-10 | Anticuerpos de quimiocina pan-elr⁺ cxc |
Country Status (36)
| Country | Link |
|---|---|
| EP (3) | EP3608336A1 (es) |
| JP (1) | JP6105146B2 (es) |
| KR (1) | KR101745230B1 (es) |
| CN (2) | CN109134652B (es) |
| AP (1) | AP2015008731A0 (es) |
| AR (2) | AR094960A1 (es) |
| AU (1) | AU2014237898B2 (es) |
| CA (1) | CA2901468C (es) |
| CL (1) | CL2015002531A1 (es) |
| CY (1) | CY1120459T1 (es) |
| DK (1) | DK2970447T3 (es) |
| EA (1) | EA029965B1 (es) |
| ES (2) | ES2769123T3 (es) |
| HK (1) | HK1212714A1 (es) |
| HR (1) | HRP20181047T1 (es) |
| HU (1) | HUE038834T2 (es) |
| IL (2) | IL241167B (es) |
| JO (1) | JO3580B1 (es) |
| LT (1) | LT2970447T (es) |
| MA (1) | MA38413A1 (es) |
| ME (1) | ME03094B (es) |
| MX (1) | MX364831B (es) |
| MY (1) | MY171213A (es) |
| NZ (1) | NZ711704A (es) |
| PE (2) | PE20191480A1 (es) |
| PH (1) | PH12015502090B1 (es) |
| PL (1) | PL2970447T3 (es) |
| PT (1) | PT2970447T (es) |
| RS (1) | RS57291B1 (es) |
| SG (1) | SG11201507686TA (es) |
| SI (1) | SI2970447T1 (es) |
| TN (1) | TN2015000377A1 (es) |
| TR (1) | TR201807613T4 (es) |
| TW (1) | TWI612059B (es) |
| UA (1) | UA116008C2 (es) |
| WO (1) | WO2014149733A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2911600A1 (en) * | 2013-05-17 | 2014-11-20 | Centre National De La Recherche Scientifique (Cnrs) | Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications |
| EP3684811A2 (en) | 2017-08-17 | 2020-07-29 | Massachusetts Institute of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
| CN111770936A (zh) | 2018-01-12 | 2020-10-13 | 百时美施贵宝公司 | 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症 |
| KR102049180B1 (ko) * | 2018-04-02 | 2019-11-26 | 고려대학교 산학협력단 | 체세포에서 유도 만능 줄기세포로의 역분화 유도용 조성물 및 이를 이용한 역분화 유도방법 |
| TWI737000B (zh) | 2018-10-22 | 2021-08-21 | 美商美國禮來大藥廠 | 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體 |
| WO2021076620A1 (en) | 2019-10-15 | 2021-04-22 | Eli Lilly And Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| WO2021163031A1 (en) * | 2020-02-12 | 2021-08-19 | Eli Lilly And Company | Crystallization of antibodies or antigen-binding fragments |
| TW202206457A (zh) | 2020-04-24 | 2022-02-16 | 美商美國禮來大藥廠 | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 |
| CN112358547A (zh) * | 2020-09-30 | 2021-02-12 | 浙江大学 | 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用 |
| WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091503A1 (en) * | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| WO2007107003A1 (en) * | 2006-03-22 | 2007-09-27 | Osteopharm Inc. | Markers for the diagnosis, monitoring and prognosis of osteoporosis and for assessing the risk for osteoporosis and for osteoporotic fractures |
| CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| PT2195023T (pt) * | 2007-08-29 | 2018-06-08 | Sanofi Sa | Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações |
| GB0806812D0 (en) * | 2008-04-15 | 2008-05-14 | Univ Leuven Kath | Citrullinated cytokines |
| CN102027015A (zh) * | 2008-05-14 | 2011-04-20 | 伊莱利利公司 | 抗cxcr4抗体 |
| PT2470671E (pt) * | 2009-08-28 | 2015-02-05 | Regeneron Pharma | Anticorpos anticinas que se ligam a múltiplas quimiocinas |
| JP2011097867A (ja) * | 2009-11-05 | 2011-05-19 | Kurume Univ | 脊柱靱帯骨化症のマーカーペプチド |
| US20120315267A1 (en) * | 2010-02-09 | 2012-12-13 | Glaxosmithkline Llc | Novel uses |
| WO2013166099A1 (en) * | 2012-05-01 | 2013-11-07 | Glaxosmithkline Llc | Novel antibodies |
-
2014
- 2014-02-27 TW TW103106908A patent/TWI612059B/zh active
- 2014-02-27 JO JOP/2014/0058A patent/JO3580B1/ar active
- 2014-02-28 AR ARP140100675A patent/AR094960A1/es active IP Right Grant
- 2014-03-05 CN CN201811074266.5A patent/CN109134652B/zh active Active
- 2014-03-05 PE PE2019001763A patent/PE20191480A1/es unknown
- 2014-03-05 PT PT147118996T patent/PT2970447T/pt unknown
- 2014-03-05 SG SG11201507686TA patent/SG11201507686TA/en unknown
- 2014-03-05 HU HUE14711899A patent/HUE038834T2/hu unknown
- 2014-03-05 MY MYPI2015703113A patent/MY171213A/en unknown
- 2014-03-05 CN CN201480013248.XA patent/CN105143259B/zh active Active
- 2014-03-05 CA CA2901468A patent/CA2901468C/en active Active
- 2014-03-05 JP JP2016500640A patent/JP6105146B2/ja active Active
- 2014-03-05 AP AP2015008731A patent/AP2015008731A0/xx unknown
- 2014-03-05 EP EP19190355.8A patent/EP3608336A1/en active Pending
- 2014-03-05 PL PL14711899T patent/PL2970447T3/pl unknown
- 2014-03-05 AU AU2014237898A patent/AU2014237898B2/en active Active
- 2014-03-05 ES ES18153438T patent/ES2769123T3/es active Active
- 2014-03-05 SI SI201430741T patent/SI2970447T1/en unknown
- 2014-03-05 DK DK14711899.6T patent/DK2970447T3/en active
- 2014-03-05 LT LTEP14711899.6T patent/LT2970447T/lt unknown
- 2014-03-05 NZ NZ711704A patent/NZ711704A/en unknown
- 2014-03-05 RS RS20180675A patent/RS57291B1/sr unknown
- 2014-03-05 MX MX2015013053A patent/MX364831B/es active IP Right Grant
- 2014-03-05 MA MA38413A patent/MA38413A1/fr unknown
- 2014-03-05 KR KR1020157024786A patent/KR101745230B1/ko active IP Right Grant
- 2014-03-05 EP EP18153438.9A patent/EP3348569B1/en active Active
- 2014-03-05 EP EP14711899.6A patent/EP2970447B1/en active Active
- 2014-03-05 WO PCT/US2014/020605 patent/WO2014149733A1/en active Application Filing
- 2014-03-05 ME MEP-2018-173A patent/ME03094B/me unknown
- 2014-03-05 EA EA201591514A patent/EA029965B1/ru not_active IP Right Cessation
- 2014-03-05 PE PE2015001961A patent/PE20151531A1/es active IP Right Grant
- 2014-03-05 ES ES14711899.6T patent/ES2675404T3/es active Active
- 2014-03-05 TR TR2018/07613T patent/TR201807613T4/tr unknown
- 2014-05-03 UA UAA201508673A patent/UA116008C2/uk unknown
-
2015
- 2015-08-31 TN TN2015000377A patent/TN2015000377A1/en unknown
- 2015-09-03 IL IL24116715A patent/IL241167B/en active IP Right Grant
- 2015-09-09 CL CL2015002531A patent/CL2015002531A1/es unknown
- 2015-09-14 PH PH12015502090A patent/PH12015502090B1/en unknown
-
2016
- 2016-01-21 HK HK16100635.3A patent/HK1212714A1/zh unknown
-
2018
- 2018-07-05 HR HRP20181047TT patent/HRP20181047T1/hr unknown
- 2018-07-24 CY CY20181100767T patent/CY1120459T1/el unknown
-
2019
- 2019-09-16 IL IL269387A patent/IL269387B/en active IP Right Grant
-
2022
- 2022-05-10 AR ARP220101240A patent/AR125831A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094960A1 (es) | Anticuerpos de quimiocina pan-elr⁺ cxc | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| CU24597B1 (es) | Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20 | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20141568A1 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| NZ738979A (en) | Pd-1 antibodies | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| PA8849001A1 (es) | Anticuerpos de c-met | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20190208A1 (es) | Anticuerpos que reconocen tau | |
| AR084315A1 (es) | Anticuerpos anti-notch1 | |
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| ES2684173T3 (es) | Anticuerpos anti-XCR1 humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |